2-Methoxyestradiol - CASI Pharmaceuticals

Drug Profile

2-Methoxyestradiol - CASI Pharmaceuticals

Alternative Names: 2ME2; CASI-2ME2; Panzem; Panzem® Capsules; Panzem® NCD

Latest Information Update: 24 Jul 2015

Price : $50

At a glance

  • Originator Childrens Hospital Boston; Harvard Medical School
  • Developer CASI Pharmaceuticals; EntreMed
  • Class Antineoplastics; Estradiol congeners; Estrenes; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Hypoxia-inducible factor-1 alpha inhibitors; Lymphocyte inhibitors; Mitosis inhibitors; NFATC-transcription-factor-inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Ovarian cancer; Multiple myeloma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Autoimmune disorders; Rheumatoid arthritis
  • Discontinued Age-related macular degeneration; Breast cancer; Carcinoid tumour; Cardiovascular disorders; Endometriosis; Glioblastoma; Multiple myeloma; Osteoporosis; Ovarian cancer; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 20 Jul 2015 Suspended - Preclinical for Autoimmune disorders in USA (PO) before July 2015
  • 27 Mar 2015 CASI Pharmaceuticals plans a phase I pharmacokinetic trial
  • 16 Jun 2014 EntreMed is now called CASI Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top